JP2019520550A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520550A5 JP2019520550A5 JP2018555652A JP2018555652A JP2019520550A5 JP 2019520550 A5 JP2019520550 A5 JP 2019520550A5 JP 2018555652 A JP2018555652 A JP 2018555652A JP 2018555652 A JP2018555652 A JP 2018555652A JP 2019520550 A5 JP2019520550 A5 JP 2019520550A5
- Authority
- JP
- Japan
- Prior art keywords
- dpp3
- pharmaceutical composition
- inhibitor
- composition according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 102100014976 DPP3 Human genes 0.000 claims 9
- 101700019464 DPP3 Proteins 0.000 claims 9
- 102000004965 antibodies Human genes 0.000 claims 8
- 108090001123 antibodies Proteins 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims 2
- 208000010125 Myocardial Infarction Diseases 0.000 claims 2
- 206010038436 Renal failure acute Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000001338 necrotic Effects 0.000 claims 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 claims 1
- 210000001124 Body Fluids Anatomy 0.000 claims 1
- 206010007554 Cardiac failure Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 210000000170 Cell Membrane Anatomy 0.000 claims 1
- 206010019280 Heart failure Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 208000007903 Liver Failure Diseases 0.000 claims 1
- 208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 206010051379 Systemic inflammatory response syndrome Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 238000002617 apheresis Methods 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 244000045947 parasites Species 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000011528 vascular disease Diseases 0.000 claims 1
Claims (11)
- 心不全、慢性心不全、急性心不全（ＡＨＦ）、心筋梗塞（ＭＩ）、卒中、肝不全、熱傷、外傷、重症感染症（微生物、ウイルス（たとえばＡＩＤＳ）、寄生虫（たとえばマラリア））、ＳＩＲＳまたは敗血症、がん、急性腎障害（ＡＫＩ）、ＣＮＳ障害（たとえば発作、神経変性疾患）、自己免疫疾患および血管疾患（たとえば川崎症候群）、ならびに低血圧症を含む群から選択される、壊死性の経過を伴うか壊死性の経過に関連する被験者の疾患または状態の予防または治療に使用するためのＤＰＰ３活性阻害剤を含む、医薬組成物。
- 前記阻害剤は抗ＤＰＰ３抗体および抗ＤＰＰ３抗体断片、ならびに抗ＤＰＰ３非Ｉｇ足場を含む群から選択される、請求項１に記載の医薬組成物。
- 前記阻害剤は単一結合特異性（ｍｏｎｏ−ｂｉｎｄｉｎｇ）または少なくとも二重結合特異性（ｔｗｏ−ｂｉｎｄｉｎｇ）の抗体である、請求項２に記載の医薬組成物。
- 前記阻害剤は、配列番号１に結合し特に配列番号２に結合する抗ＤＰＰ３抗体または抗ＤＰＰ３抗体断片、あるいは抗ＤＰＰ３非Ｉｇ足場である、請求項２または３に記載の医薬組成物。
- 前記阻害剤はＤＰＰ３に対し１０-7Ｍ以下の最低結合親和性を示す抗体または断片あるいは足場である、請求項２〜４のいずれか一項に記載の医薬組成物。
- 前記阻害剤は単一特異性の抗体または断片あるいは足場である、請求項２〜５のいずれか一項に記載の医薬組成物。
- 前記阻害剤はモノクローナル抗体である、請求項２〜６のいずれか一項に記載の医薬組成物。
- 前記阻害剤は、全長ＤＰＰ３に結合しＤＰＰ３の活性を少なくとも１０％または少なくとも５０％、より好ましくは少なくとも６０％、さらに好ましくは７０％超、さらに好ましくは８０％超、さらに好ましくは９０％超、さらに好ましくは９５％超、阻害する抗体または断片あるいは足場である、請求項２〜７のいずれか一項に記載の医薬組成物。
- 前記阻害剤はＤＰＰ３に選択的かつ／または特異的であり、かつ細胞膜および／または血液脳関門を通過しない、請求項２〜８のいずれか一項に記載の医薬組成物。
- 前記被験者は、体液試料中に所定の閾値を超えるＤＰＰ３総量および／または活性ＤＰＰ３の量を有する、請求項２〜９のいずれか一項に記載の医薬組成物。
- アフェレーシスと親和性クロマトグラフィーを含む、血漿からＤＰＰ３を体外除去する方法における請求項２〜１０のいずれか一項に記載のＤＰＰ３活性阻害剤の使用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110620A JP2022163014A (ja) | 2016-04-21 | 2022-07-08 | Ｄｐｐ３の定量方法および治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16166476.8 | 2016-04-21 | ||
| EP16166476 | 2016-04-21 | ||
| PCT/EP2017/059377 WO2017182561A1 (en) | 2016-04-21 | 2017-04-20 | Methods for determining dpp3 and therapeutic methods |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020076521A Division JP7219737B2 (ja) | 2016-04-21 | 2020-04-23 | Ｄｐｐ３の定量方法および治療方法 |
| JP2022110620A Division JP2022163014A (ja) | 2016-04-21 | 2022-07-08 | Ｄｐｐ３の定量方法および治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019520550A JP2019520550A (ja) | 2019-07-18 |
| JP2019520550A5 true JP2019520550A5 (ja) | 2020-05-28 |
Family
ID=56014788
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555652A Pending JP2019520550A (ja) | 2016-04-21 | 2017-04-20 | Ｄｐｐ３の定量方法および治療方法 |
| JP2020076521A Active JP7219737B2 (ja) | 2016-04-21 | 2020-04-23 | Ｄｐｐ３の定量方法および治療方法 |
| JP2022110620A Pending JP2022163014A (ja) | 2016-04-21 | 2022-07-08 | Ｄｐｐ３の定量方法および治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020076521A Active JP7219737B2 (ja) | 2016-04-21 | 2020-04-23 | Ｄｐｐ３の定量方法および治療方法 |
| JP2022110620A Pending JP2022163014A (ja) | 2016-04-21 | 2022-07-08 | Ｄｐｐ３の定量方法および治療方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190145981A1 (ja) |
| EP (3) | EP3854817A1 (ja) |
| JP (3) | JP2019520550A (ja) |
| KR (2) | KR20230123520A (ja) |
| CN (1) | CN110168372A (ja) |
| AU (2) | AU2017252212B2 (ja) |
| BR (1) | BR112018071583A2 (ja) |
| CA (1) | CA3021252A1 (ja) |
| CH (1) | CH713803B1 (ja) |
| DE (1) | DE112017002105T5 (ja) |
| IL (1) | IL262472A (ja) |
| MX (2) | MX2018012856A (ja) |
| SG (1) | SG11201809252YA (ja) |
| WO (1) | WO2017182561A1 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200083509A (ko) | 2017-10-25 | 2020-07-08 | 4틴4 파마슈티컬스 게엠베하 | 특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도 |
| CN113557031A (zh) * | 2018-12-21 | 2021-10-26 | 4Teen4制药有限公司 | 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测 |
| JP2023515985A (ja) | 2020-02-27 | 2023-04-17 | アドレノメト アクチェンゲゼルシャフト | ショック状態の患者の治療において使用するための抗アドレノメデュリン（ａｄｍ）結合剤 |
| IL295728A (en) | 2020-02-27 | 2022-10-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm backbone without ig for use in the treatment of cure or prevention of shock |
| WO2021170838A1 (en) | 2020-02-27 | 2021-09-02 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
| WO2021185786A1 (en) * | 2020-03-16 | 2021-09-23 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| EP3922993A1 (en) * | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
| CN117186177A (zh) * | 2022-05-31 | 2023-12-08 | 中国农业大学 | 一种具有降尿酸活性的鸭血球蛋白肽及其制备方法 |
| WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
| WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| WO2024126793A1 (en) | 2022-12-15 | 2024-06-20 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitor for improvement of pulmonary function in critically ill patients |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| JPS6188884A (ja) | 1984-10-04 | 1986-05-07 | Sankyo Co Ltd | エンケフアリナ−ゼｂ阻害物質およびその製法 |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH06219989A (ja) * | 1993-01-27 | 1994-08-09 | Microbial Chem Res Found | 新規生理活性物質フルオスタチンａおよびｂ、その製造法およびその用途 |
| US5612186A (en) | 1994-06-22 | 1997-03-18 | Food Industry Research And Development Institute | Enzyme-capture assay (ECA) for the identification of Escherichia coli in clinical samples |
| US5601986A (en) | 1994-07-14 | 1997-02-11 | Amgen Inc. | Assays and devices for the detection of extrahepatic biliary atresia |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU6949200A (en) | 1999-09-01 | 2001-03-26 | Incyte Genomics, Inc. | Human hydrolytic enzymes |
| WO2002038742A2 (en) * | 2000-11-08 | 2002-05-16 | The University Of Georgia Research Foundation, Inc. | Dipeptidylpeptidases and methods of use |
| US20040023334A1 (en) | 2001-08-30 | 2004-02-05 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
| CN1852974A (zh) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | 用于治疗和诊断癌症的组合物和方法 |
| AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| WO2005106486A2 (en) * | 2004-04-28 | 2005-11-10 | Bayer Healthcare Ag | Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3) |
| JPWO2005118842A1 (ja) * | 2004-06-01 | 2008-04-03 | シスメックス株式会社 | 酵素活性測定方法および酵素活性測定用カラム |
| EP1793847A2 (en) | 2004-09-21 | 2007-06-13 | NascaCell IP GmbH | Use of microproteins as tryptase inhibitors |
| JP2006230318A (ja) * | 2005-02-25 | 2006-09-07 | Maruishi Pharmaceutical Co Ltd | 関節リウマチの診断方法 |
| CN100420947C (zh) * | 2005-05-30 | 2008-09-24 | 孙东旭 | 用单一捕获剂定量检测特异性分析物的方法及其试剂盒 |
| US8652789B2 (en) | 2006-03-13 | 2014-02-18 | Becton, Dickinson And Company | Diagnosis and prognosis of dipeptidyl peptidase-associated disease states |
| US20080057590A1 (en) | 2006-06-07 | 2008-03-06 | Mickey Urdea | Markers associated with arteriovascular events and methods of use thereof |
| WO2009077175A1 (en) | 2007-12-19 | 2009-06-25 | Affibody Ab | Polypeptide derived from protein a and able to bind pdgf |
| JP5954990B2 (ja) | 2008-11-03 | 2016-07-20 | モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ | Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質 |
| US8715928B2 (en) * | 2009-02-13 | 2014-05-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molecular-based method of cancer diagnosis and prognosis |
| NZ598351A (en) | 2009-08-27 | 2014-08-29 | Covagen Ag | Il-17 binding compounds and medical uses thereof |
| WO2011073209A1 (en) | 2009-12-14 | 2011-06-23 | Scil Proteins Gmbh | Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin |
| KR101234352B1 (ko) * | 2010-03-18 | 2013-02-15 | 권동락 | 선택적 면역 세포 분리 반출장치 |
| NZ603562A (en) | 2010-06-08 | 2014-07-25 | Pieris Ag | Tear lipocalin muteins binding il-4 r alpha |
-
2017
- 2017-04-20 EP EP21153574.5A patent/EP3854817A1/en active Pending
- 2017-04-20 EP EP17720047.4A patent/EP3446125A1/en active Pending
- 2017-04-20 WO PCT/EP2017/059377 patent/WO2017182561A1/en active Application Filing
- 2017-04-20 KR KR1020237026743A patent/KR20230123520A/ko not_active Application Discontinuation
- 2017-04-20 AU AU2017252212A patent/AU2017252212B2/en active Active
- 2017-04-20 MX MX2018012856A patent/MX2018012856A/es unknown
- 2017-04-20 CH CH001280/2018A patent/CH713803B1/de not_active IP Right Cessation
- 2017-04-20 US US16/095,563 patent/US20190145981A1/en active Pending
- 2017-04-20 KR KR1020187033194A patent/KR102565453B1/ko active IP Right Grant
- 2017-04-20 DE DE112017002105.7T patent/DE112017002105T5/de active Pending
- 2017-04-20 EP EP21153560.4A patent/EP3896450A1/en active Pending
- 2017-04-20 SG SG11201809252YA patent/SG11201809252YA/en unknown
- 2017-04-20 CA CA3021252A patent/CA3021252A1/en active Pending
- 2017-04-20 JP JP2018555652A patent/JP2019520550A/ja active Pending
- 2017-04-20 BR BR112018071583-2A patent/BR112018071583A2/pt unknown
- 2017-04-20 CN CN201780039077.1A patent/CN110168372A/zh active Pending
-
2018
- 2018-10-18 IL IL262472A patent/IL262472A/en unknown
- 2018-10-19 MX MX2020001193A patent/MX2020001193A/es unknown
-
2020
- 2020-04-23 JP JP2020076521A patent/JP7219737B2/ja active Active
- 2020-07-02 US US16/919,449 patent/US11726094B2/en active Active
-
2022
- 2022-07-08 JP JP2022110620A patent/JP2022163014A/ja active Pending
-
2023
- 2023-11-02 AU AU2023258417A patent/AU2023258417A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520550A5 (ja) | ||
| JP2017113019A5 (ja) | ||
| Su et al. | HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17‐cell expansion | |
| Meyer et al. | Rheumatoid arthritis and risk of cardiovascular disease | |
| JP2008523083A5 (ja) | ||
| Apostolakis et al. | Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway | |
| Eppensteiner et al. | Immunothrombotic activity of damage-associated molecular patterns and extracellular vesicles in secondary organ failure induced by trauma and sterile insults | |
| Chatterjee et al. | SDF‐1α induces differential trafficking of CXCR4‐CXCR7 involving cyclophilin A, CXCR7 ubiquitination and promotes platelet survival | |
| Noiri et al. | Role of vascular endothelial growth factor in kidney disease | |
| JP2016183160A5 (ja) | ||
| JP2014518883A5 (ja) | ||
| JP2019506159A5 (ja) | ||
| JP2011503012A5 (ja) | ||
| JP2011184466A5 (ja) | ||
| Cong et al. | Plasma membrane wounding and repair in pulmonary diseases | |
| JP2016529229A5 (ja) | ||
| Han et al. | Renal recruitment of B lymphocytes exacerbates tubulointerstitial fibrosis by promoting monocyte mobilization and infiltration after unilateral ureteral obstruction | |
| Steckelings et al. | Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists | |
| JP2016539121A5 (ja) | ||
| JP2009508822A5 (ja) | ||
| JP2013539454A5 (ja) | ||
| FI3553084T3 (fi) | Anti-adrenomedulliinivasta-aine (ADM) tai anti-ADM-vasta-ainefragmentti tai anti-ADM-non-Ig-skaffoldi elimen toimintahäiriön tai elimen vajaatoiminnan ehkäisemiseksi tai pienentämiseksi kroonisen tai akuutin taudin tai akuutin tilan omaavassa potilaassa | |
| Damås et al. | Increased levels of soluble CD40L in African tick bite fever: possible involvement of TLRs in the pathogenic interaction between Rickettsia africae, endothelial cells, and platelets | |
| JP2016520594A5 (ja) | ||
| Li et al. | Staphylococcal superantigens use LAMA2 as a coreceptor to activate T cells |